BLSM (BlossomHill Therapeutics) Other Long-Term Liabilities: $256.82 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BLSM BlossomHill Therapeutics Inc BLSM
8 GF Score
Price $15.99
View Full Analysis

What is BlossomHill Therapeutics Other Long-Term Liabilities?

BlossomHill Therapeutics BLSM -0.06% 8 Other Long-Term Liabilities is $256.82 Mil as of Dec. 2025. GuruFocus rates BLSM with a GF Score™ of 8/100.

BlossomHill Therapeutics's other long-term liabilities for the quarter that ended in Dec. 2025 was $256.82 Mil.

BlossomHill Therapeutics's quarterly other long-term liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($172.89 Mil) and increased from Dec. 2024 ($172.89 Mil) to Dec. 2025 ($256.82 Mil).

BlossomHill Therapeutics's annual other long-term liabilities increased from . 20 ($0.00 Mil) to Dec. 2024 ($172.89 Mil) and increased from Dec. 2024 ($172.89 Mil) to Dec. 2025 ($256.82 Mil).

BlossomHill Therapeutics Other Long-Term Liabilities Related Terms

BlossomHill Therapeutics Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for BlossomHill Therapeutics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BlossomHill Therapeutics Other Long-Term Liabilities Chart

BlossomHill Therapeutics Annual Data
Trend Dec24 Dec25
Other Long-Term Liabilities
172.89 256.82

BlossomHill Therapeutics Semi-Annual Data
Dec24 Dec25
Other Long-Term Liabilities 172.89 256.82
BLSM
8GF Score
BlossomHill Therapeutics Inc BLSM
Other Long-Term Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BlossomHill Therapeutics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $256.82 Mil mean?
BlossomHill Therapeutics (BLSM) has a Other Long-Term Liabilities of $256.82 Mil as of Dec. 2025. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on BlossomHill Therapeutics and its competitors.
Is BlossomHill Therapeutics' Other Long-Term Liabilities too high?
BlossomHill Therapeutics' current Other Long-Term Liabilities is $256.82 Mil. Overall, BlossomHill Therapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does BlossomHill Therapeutics' Other Long-Term Liabilities compare to ?
BlossomHill Therapeutics' Other Long-Term Liabilities of $256.82 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on BlossomHill Therapeutics and its competitors. BlossomHill Therapeutics's current Other Long-Term Liabilities is $256.82 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BlossomHill Therapeutics stock overvalued right now?
BlossomHill Therapeutics (BLSM) has a current Other Long-Term Liabilities of $256.82 Mil. The current Other Long-Term Liabilities is $256.82 Mil. BlossomHill Therapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For BlossomHill Therapeutics (BLSM), the current Other Long-Term Liabilities is $256.82 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BlossomHill Therapeutics Business Description

Comparable Companies
Address 10255 Science Center Drive, Suite 200, San Diego, CA, USA, 92121
BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying its intentional, chemistry-based approach to develop small molecule medicines that address unmet medical needs in cancer treatment. Its product pipeline includes two clinical-stage programs: BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor being evaluated first in relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndromes (HR-MDS), and the preclinical-stage product candidate BH-501284 targeting activated KRAS.
8GF Score

Get the complete analysis for BLSM

Other Long-Term Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$15.99
Price